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ABSTRACT MicroRNAs (miRNAs) constitute an evolution-
arily conserved class of small non-coding RNAs that are
endogenously expressed with crucial functions in fundamental
cellular processes such as cell cycle, apoptosis and differentiation.
Disturbance of miRNA expression and function leads to
deregulation of basic cellular processes leading to tumorigenesis.
A growing body of experimental evidence suggests that human
tumors have deregulated expression of microRNAs, which have
been proposed as novel oncogenes or tumor suppressors.
Recent studies have shown that microRNA expression patterns
serve as phenotypic signatures of different cancers and could be
used as diagnostic, prognostic and therapeutic tools. A few
studies have analyzed global microRNA expression profiles or
the functional role of microRNAs in prostate cancer. Here we
have reviewed the role of microRNAs in prostate carcinogenesis
bysummarizing thefindings fromsuch studies.Inaddition,recent
evidence indicates that dietary factors play an important role in
the process of carcinogenesis through modulation of miRNA
expression, though such studies are lacking in regards to prostate
cancer. It has been proposed that dietary modulation of miRNA
expression may contribute to the cancer-protective effects of
dietarycomponents.Inthisreview,wehavesummarizedfindings
from studies ontheeffectofdietaryagentson miRNAexpression
and function.
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INTRODUCTION
MicroRNAs are small (∼22 nucleotides) endogenously
expressed non-coding RNAs that regulate gene expression.
It is being increasingly recognized that microRNAs constitute
an important class of gene modulators that play crucial roles
in almost every cellular process that has been investigated,
including the cell cycle, apoptosis, development, differentia-
tion and metabolism. It has been estimated that miRNAs
regulate ∼30% of the human genome (1). Given the crucial
role of these small RNAs in fundamental cellular processes,
it is not surprising that the deregulated expression of
microRNAs leads to various disease states, including cancer.
Environmental and dietary factors are believed to con-
tribute to differences in cancer incidence among populations
with different dietary habits. A growing body of literature
suggests that dietary factors play a role in carcinogenesis.
Several studies suggest that dietary components act as
chemopreventive agents in prostate carcinogenesis (2). Pros-
tate cancer statistics point to differences in cancer incidences
amongst populations with different dietary habits. Dietary
components potentially influence fundamental cellular pro-
cesses involved in carcinogenesis, including apoptosis, cell-
cycle control, angiogenesis, inflammation and DNA repair.
Since miRNAs also play a central role in controlling these
cellular processes, it is intuitive that diet and microRNAs co-
operatively regulate the process of tumorigenesis. A few
reports discussed below suggest that dietary modulation of
miRNA expression may contribute to the cancer-protective
effects of dietary components. However, this is an area that is
largely underexplored, in particular in prostate cancer, and
warrants further investigation.
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MicroRNAs regulate the expression of protein-coding genes
largely at the post-transcriptional level. It has been
estimated that miRNAs regulate ∼30% of the human
genome (1). MicroRNA genes are evolutionarily conserved
and are located within the introns or exons of protein-
coding genes (70%) or in intergenic regions (30%) (3). Most
of the intronic or exonic miRNAs are oriented in sense with
their host gene, suggesting that their transcription occurs in
parallel with the transcription of the host gene. Additionally,
some miRNAs are clustered in polycistronic transcripts,
enabling a coordinated expression. The miRNAs in inter-
genic regions or in isolated regions of the genome are
transcribed independently (3). MicroRNAs are preferentially
transcribed by RNA polymerase II into large precursor
RNAs, often several kilobases in length, called primary
miRNAs (pre-miRNAs) (4–6). These pri-miRNAs of long
nucleotide sequence are usually capped at the 5’end and
polyadenylated at the 3’ regions (5). Pri-miRNAs form
specific hairpin-shaped stem-loop secondary structures and
are cleaved by nuclear RNase III Drosha to release a
miRNA precursor (pre-miRNA) that is about 60–75
nucleotides in length (7,8). Drosha also requires a protein
cofactor, DGCR8 or Pasha (9). In humans, Drosha and
Pasha form a large complex known as the microprocessor
complex (10). The pre-miRNAs are then exported to the
cytoplasm by exportin-5 (11,12) where they are further
processed by the enzyme Dicer, a second RNase III
enodnuclease, resulting in a mature double-stranded
miRNA (19–24 nucleotides) (13,14). The functional strand
of this mature miRNA is incorporated into an effector
complex, called the RNA-induced silencing complex (RISC),
which functions to silence gene expression (14,15). The
opposite strand is eliminated by cleavage. MicroRNAs
regulate their targets by direct cleavage of the mRNA or
by inhibition of protein synthesis. Perfect or nearly perfect
complementarity between the miRNA and its target 3’UTR
induces RISC to cleave the target mRNA, whereas
imperfect base matching induces mainly translational
silencing of the target gene. MicroRNAs can also direct
deadenylation of the target mRNA that leads to either
mRNA decay or reduces its level (14).
Recent studies from our laboratory have provided a novel
concept that miRNAs and non-coding double-stranded
RNAs (dsRNAs) can activate various tumor suppressor
genes (16–18). By scanning gene promoters in silico for
sequences complementary to known miRNAs, we identified
a putative miR-373 target site in the promoter of E-
cadherin. Transfection of miR-373 or its precursor hairpin
RNA (pre-miR-373) into prostate cancer PC-3 cells readily
induced E-cadherin expression (17) by targeting its specific
site in the gene promoter. Another report suggests that
several microRNAs, including Let7, induce translational
upregulation of target mRNAs on cell-cycle arrest, yet they
repress translation in proliferating cells (19). Another study
supports the concept that microRNA can directly bind to
promoter regions in cis and mediate transcriptional gene
silencing (20). Additionally, specific miRNAs that carry a
distinct hexanucleotide terminal motif, such as miR-29b,
were found enriched in the nucleus, suggesting extra miRNA
functions in distinct subcellular compartments (21). The
ability for miRNAs to act through pleiotropic mechanisms
points to the fundamental importance of miRNAs in
regulating gene expression as crucial regulatory elements in
fundamental biological processes. Recently, proteomic stud-
ies were used to study the impact of a single miRNA on
global changes in protein expression, and it was found that a
single miRNA can impact on hundreds of targets (22,23).
ROLE OF MICRORNA IN CANCER: A PLETHORA
OF MECHANISMS
Disturbances in the expression of miRNAs, processing of
miRNA precursors or mutations in the sequence of the
miRNA, its precursor, or its target mRNA, may have
detrimental effects on cellular function and have been
associated with cancer (24). Strikingly, half of the known
miRNA genes are located inside or close to fragile genomic
sites and in minimal regions of loss of heterozygosity,
minimal regions of amplifications, and common break-
points associated with cancer (25). It has been proposed
that microRNAs may regulate tumorigenesis through a
plethora of possible oncogenic mechanisms (26). Genomic
deletion or epigenetic silencing of a miRNA that normally
represses expression of one or more oncogenes might lead
to increased oncogenic expression. Alternatively, amplifica-
tion, overexpression, or loss of epigenetic silencing of a gene
encoding an miRNA that targets one or more tumor
suppressor genes could inhibit the activity of an anti-
oncogenic pathway (26). In addition, mutations affecting
the sequence of the mature miRNA or target mRNA could
alter binding of the miRNA to its cognate targets leading to
alterations in the balance of critical growth regulatory
proteins. MicroRNAs can act as oncogenes or tumor
suppressor genes (27). Examination of tumor-specific
miRNA expression profiles has revealed widespread dys-
regulation of these molecules in diverse cancers. Over-
expressed miRNAs in cancers, such as mir-17-92 cluster,
may function as oncogenes and promote cancer develop-
ment by negatively regulating tumor suppressor genes and/
or genes that control cell differentiation or apoptosis. The
onco-microRNA expression profiling of human malignan-
cies has also identified a number of diagnostic and
MicroRNAs and Prostate Cancer 1015prognostic cancer signatures (28). Also, some microRNAs
are downregulated in cancer and act as bona fide tumor
suppressor genes, such as let-7 and miR-34a. The wide-
spread differential expression of miRNA genes between
malignant and normal cells is a complex phenomenon and
may involve multiple mechanisms, including miRNA
transcriptional control by tumour suppressor genes, onco-
genes, epigenetic mechanisms and genomic abnormalities
(26,27). For example, the tumour suppressor miR-34a is
transactivated by the tumor suppressor p53, is kept in check
by MYC, is silenced by aberrant CpG methylation, and is
located at 1p36, a chromosomal region that is frequently
lost in neuroblastomas (29–34).
MicroRNA: Cancer Initiation and Progression
Cancer initiation and progression can involve miRNAs, and
their expression profiles can be used for the classification,
diagnosis, and prognosis of human malignancies. Loss or
amplification of miRNA genes has been reported in a variety
of cancers, and altered patterns of miRNA expression may
affect cell cycle and survival programs. Germ-line and
somatic mutations in miRNAs or polymorphisms in the
mRNAs targeted by miRNAs may also contribute to cancer
predisposition and progression. It has been proposed that
alterations in miRNA genes play a critical role in the
pathophysiology of many, perhaps all, human cancers (35).
MicroRNAs: Tumor Invasion and Metastasis
A role for miRNAs has been established in the later steps of
tumorigenesis, progression, and metastasis. More than 20
miRNAs have been shown to impact critical steps in the
metastatic cascade, such as epithelial-mesenchymal transition
(EMT), apoptosis, and angiogenesis, by acting on multiple
signaling pathways and targeting various proteins that are
major players in this process. Eleven different miRNAs have
been directly shown to promote or inhibit metastasis in
experimental models of various cancers (36). Furthermore,
several clinical studies have identified correlations between
miRNA expression and recurrence, development of metas-
tases and/or survival (36,37). As an example, miR-10b
seems to play an important role in metastasis. miR-10b is
highly expressed in metastatic breast cancer cells and posi-
tively regulates cell migration and invasion. (38). Further,
expression of miR-10b is induced by the transcription factor
Twist that binds directly to the putative promoter of miR-
10b and transcriptionally activates this miR which further
leads to repression of homeobox D10 (HOXD10). This
results in increased expression of a well-characterized pro-
metastatic gene, RHOC. Significantly, the level of miR-10b
expression in primary breast carcinomas correlates with
clinical progression (38). These findings exemplify a complex
regulatory pathway, in which a pleiotropic transcription
factor induces expression of a specific microRNA, which
suppresses its direct target and in turn activates another pro-
metastatic gene, leading to tumor cell invasion and metastasis.
In summary, studies suggest that miRNAs are involved in
the initiation, progression and metastasis of various cancers.
MICRORNA AND PROSTATE CANCER
Prostate cancer (PCa) is the most common male malignancy
and the second leading cause of cancer death among men in
the United States with an estimated 192, 280 new cases and
27,360 deaths in 2009. The precise molecular mechanisms
underlying the development and progression of prostate
cancer remain poorly understood. It is now recognized that
the process of prostate cancer development is a consequence
of genetic and epigenetic alterations that transform normal
glandular epithelium to preneoplastic lesions that lead to
invasive carcinoma (39,40). Clinically, prostate cancer is
diagnosed as local or advanced, and treatments include sur-
veillance, radiotherapy, radical prostatectomy or androgen-
deprivation. Surgery and radiation are generally effective
against clinically localized PCa; however, metastatic prostate
cancer invariably remains incurable. Androgen ablation
therapy for advanced prostate cancer reduces symptoms in a
majority of patients, but most tumors relapse within 2 years to
an incurable hormone-independent state causing mortality
(41). The underlying regulatory mechanisms that cause this
transition remain largely unknown, and, at present, there is
no effective therapy for metastatic prostate cancer. Also,
there is an urgent need to develop better diagnostic and
prognostic indicators for predicting the severity of the
disease. This emphasizes the need for a better understanding
of the molecular pathogenesis of prostate cancer which could
lead to better diagnostic and therapeutic interventions for
the disease. Recent studies have shown that microRNAs are
significantly altered in prostate cancer, suggesting that
miRNAs act as key regulators of prostate carcinogenesis.
Several studies have been conducted to identify the PCa-
specific miRNA signature. However, no consensus has been
reached on which miRNAs are relevant for development
and progression of this malignancy (42,43). Below, we
summarize the results obtained from miRNA expression
profiling studies and single miRNA-focused functional
studies carried out in prostate cancer.
MICRORNA PROFILING STUDIES IN PROSTATE
CANCER
Lu et al. (2005) performed a systematic expression analysis
of 217 mammalian miRNAs from 334 samples, including
1016 Saini, Majid and Dahiyamultiple human cancers using a bead-based flow cytometric
expression profiling method and observed a general down-
regulation of miRNAs in tumors compared with normal
tissues (44). Volinia et al. (2006) conducted a large-scale
microarray analysis on six solid tumors (including lung,
breast, stomach, prostate, colon, and pancreatic tumors)
and identified a common miRNA signature for solid tumors
largely composed of overexpressed miRNAs, such as miR-
17-5p, miR-20a, miR-21, miR-92, miR-106a, and miR-155
(45). In the prostate cancer subset, 56 tumor tissues and 7
tissues from non-cancerous subjects were analysed. This
analysis showed that 39 miRs were upegulated and 6
downregulated in prostate cancer, suggesting that gain of
miRNA expression rather than loss is a more frequent event
in prostate tumorigenesis (45).
Porkka et al. (2007) first identified the miRNA signature
specific for prostate cancer in a study on 6 prostate cancer
cell lines, 9 prostate cancer xenografts, 4 benign prostatic
hyperplasia (BPH), and 9 prostate carcinoma samples (5
untreated and 4 hormone-refractory) using an oligonucle-
otide array hybridization method (46) Differential expres-
sion of 51 individual miRNAs (14 upregulated and 37
downregulated) was found between non-malignant tissues
and carcinomas. Hierarchical clustering of the tumor
samples by their miRNA expression accurately separated
the carcinomas from the BPH samples and also further
classified the carcinoma tumors according to their andro-
gen dependence (hormone naïve versus hormone refractory),
indicating the potential of miRNAs as a novel diagnostic
and prognostic tool for prostate cancer. Also, there was a
significant trend between the expression of miRNAs and
miRNA locus copy number determined by array compar-
ative genomic hybridization, indicating that genetic aberra-
tions may target miRNAs (46). In another study, Ozen et al.
(2008) analyzed expression of 480 human miRNAs in 10
benign peripheral zone tissues and 16 prostate cancer
tissues using microarray-based profiling and found wide-
spread downregulation of miRNAs in clinically localized
prostate cancer relative to the benign peripheral zone tissue
(47). Expression data for select miRNAs, including miR-
125b, miR-145 and let-7c, was confirmed by real-time RT-
PCR assays. The downregulated miRNAs included several
with proven target mRNAs whose proteins have been
previously shown to be increased in prostate cancer by
immunohistochemistry, including RAS, E2F3, BCL-2 (47).
Ambs et al. (2008) performed a genome-wide expression
profiling of microRNAs and mRNAs in 60 primary
prostate tumors and 16 non-tumor prostate tissues (48).
The mRNA analysis revealed that key components of
microRNA processing and several genes harboring miRNA
coding sequences in their introns, e.g., MCM7 and C9orf5,
were significantly upregulated in prostate tumors. Consis-
tent with these findings, tumors expressed the miR-106b-25
cluster, which maps to intron 13 of MCM7, and miR-32,
which maps to intron 14 of C9orf5, at significantly higher
levels than non-tumor prostate. Additional differences in
microRNA abundance were found between organ-confined
tumors and those with extraprostatic disease extension (48).
Also, this study provided evidence that some microRNAs
are androgen-regulated. Those included miR-338 and
miR-126 and the miR-181b-1, miR-181c, miR-221 clus-
ters, among others. A motif search showed that these
microRNAs have putative androgen receptor binding sites
in their flanking regions (48). Also, miRNA expression
profiling of tumors with perineural (PNI) invasion showed
differential expression of 19 microRNAs in PNI tumors
than in non-PNI tumors, where miR-224 was reported to
be the most differently expressed microRNA (49).
In another effort, Tong et al. (2009) conducted paired
miRNA profiling analysis of normal and microdissected
malignant tissues of prostatectomy specimens from 40
patients diagnosed with stage T2 prostate cancer to charac-
terize the miRNA expression profile in early disease (50).
This study showed that five miRNAs (miR-23b, -100, -145, -
221 and -222) were significantly downregulated in malignant
tissues. Further, differential miRNA expression (miR-194
and -135b overexpression) was found in patients with early
chemical relapse (<2 years post-prostatectomy) and those
without clinical relapse for a period of more than 10 years
(48). This suggests that altered miRNA expression accom-
panies the prostate oncogenic process, with the early relapse
subset earmarked by additional aberrant miRNA features
prior to clinical relapse.
A recent study implemented a systems biology approach
to identify microRNAs and gene regulatory networks that
contribute to the aggressive phenotype of prostate cancer
and evaluated transcriptional profiles of 125 lymphoblas-
toid cell lines derived from 62 aggressive (Gleason grade≥8)
and 63 nonaggressive (Gleason grade≤5) prostate cancer
patients. This study identified a set of cell cycle-related
genes and miRNAs whose expression levels are associated
with prostate cancer aggressiveness. From 273 miRNAs
tested, seven different miRNAs, including miR-222, miR-
221, miR-331-3p, miR-16, miR-145, miR-9*, and miR-
551a, showed a significant association with prostate cancer
grade (51). Ribas et al. (2009) identified a set of 16
androgen-responsive miRNAs using high-throughput
microarray analysis on two AR-positive prostate cancer
(CaP) cell lines LNCaP and LAPC-4 (52).
SINGLE-MIRNA FOCUSED STUDIES IN PROSTATE
CANCER
There have been a few single-miRNA focused studies in
prostate cancer, where the functional role of specific
MicroRNAs and Prostate Cancer 1017miRNAs has been thoroughly investigated. Based on these
studies, a small number of miRNAs have been charac-
terized as potential tumor suppressors or oncogenes in
prostate cancer as reviewed in the following sections. The
key findings from such studies are summarized in Fig. 1.
Tumor Suppressor MicroRNA in Prostate Cancer
Bonci et al. (2008) reported the frequent downregulation of
miR-15a/miR-16 levels in prostate carcinomas (53). Q-
PCR analysis of 20 prostate tumor-derived primary cultures
compared to their normal counterparts, and in situ
hybridization analysis of 15 prostate tumor biopsies showed
that miR-15a/miR-16 levels are downregulated in the vast
majority of the cases (up to 85% of the samples). Delivery of
antagomirs specific for miR-15a and miR-16 to normal
mouse prostate results in marked hyperplasia, and knock-
down of miR-15a and miR-16 promotes survival, prolifer-
ation and invasiveness of untransformed prostate cells,
which become tumorigenic in immunodeficient NOD-
SCID mice. These observations were, at least in part,
explained by the evidence that miR-15a/miR-16 are able
to post-transcriptionally repress the expression of Bcl2,
CCND1 (i.e. Cyclin D1) and WNT3A, thus interfering with
multiple oncogenic activities (53). Also, a recent report
implicates a role of miR-15a/miR-16 in the control of
angiogenesis by regulating VEGF levels (54).
miR-23a and miR-23b are significantly decreased in
human prostate cancer as compared with normal prostate
tissue (46). miR-23a and miR-23b are transcriptionally
repressed by c-Myc in PC3 prostate cancer cells, resulting
in upregulated expression of their target protein, mitochon-
drial glutaminase (55). This leads to upregulation of
glutamine catabolism, conferring a growth advantage to
cancer cells.
miR-34a has been implicated as a target of the tumor
suppressor p53 (29,30) and represents a tumor suppressor
gene which is inactivated by CpG methylation and
subsequent transcriptional silencing in a broad range of
tumors, including prostate cancer (33). In prostate cancer
cell lines, miR-34a expression is markedly reduced in p53-
null PC3 cells and p53-mutated DU145 cells compared
with LNCaP cells expressing wild-type p53 (56). In PC3
cells, ectopic miR-34a expression resulted in cell-cycle
arrest, growth inhibition, senescence and attenuated chemo-
resistance to anticancer drug camptothecin by inducing
apoptosis, suggesting a potential role of miR-34a for the
treatment of p53-defective prostate cancer. Cyclin depen-
dent kinase 6 (CDK6) and deacetylase sirtuin SIRT1 have
been identified as targets of miR-34a (33,56). SIRT1
regulates p53-dependent apoptosis through deacetylating
Fig. 1 Summarized results
from single-miRNA focused
functional studies in prostate
cancer. A schematic representa-
tion of microRNAs and their
targets that have been directly
shown to affect epigenetic
reprogramming, cell growth,
apoptosis, invasion, migration,
EMT (epithelial-to-mesenchymal
transition) and androgen-
independent growth in prostate
cancer. MicroRNAs are defined as
tumor-suppressive or oncogenic
based on their expression patterns
and functional targets in prostate
cancer.
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miR-34a activation of apoptosis by regulating p53 activity,
suggesting a positive feedback loop in which p53 induces
expression of miR-34a, which suppresses SIRT1, increasing
p53 activity (57,58).
miR-101 expression decreases during prostate cancer
progression due to loss of one or both of the two genomic loci
encoding miR-101 (59). Appoximately 37.5% of clinically
localized prostate cancers (6/16) and 66.7% of metastatic
disease (22/33) showed a genomic loss of miR-101. miR-
101 inhibits the expression and function of a polycomb
group member, enhancer of zeste homolog 2 (EZH2), in
prostate cancer, suggesting that genomic loss of miR-101 in
cancer leads to overexpression of EZH2 and concomitant
dysregulation of epigenetic pathways, resulting in cancer
progression (59). Studies show a tumor-suppressive role for
miR-449a as well (60). miR-449a is downregulated in
prostate cancer tissues relative to patient-matched normal
control tissues (60). Introduction of miR-449a into PC-3
prostate cancer cells resulted in cell-cycle arrest, apoptosis
and a senescent-like phenotype. miR-449a directly targets
HDAC1, which is frequently overexpressed in prostate
cancer (60,61).
Expression of miR-100, miR-218 and miR-let7c has been
reported to be markedly reduced in metastatic cancer com-
pared with localized high-grade disease (62). A recent study
shows that miR-143 levels are inversely correlated with
advanced stages of prostate cancer (63). Rescue of miR-143
expression in prostate cancer cells leads to the inhibition of
extracellular signal-regulated kinase-5 (ERK5) activity and
concomitant growth arrest in vitro and in vivo (63).
Recent studies have shown that the miR-200 family
regulatesepithelial-mesenchymaltransition(EMT)bydirectly
targeting the E-cadherin transcriptional repressors ZEB1
(zinc-finger E-box binding homeobox 1) and ZEB2 (SMAD-
interacting protein 1 (SIP1) (64). miR-200 is significantly
downregulated in EMT induced by platelet-derived growth
factor-D in PC-3 cells (65). miR-200b restoration led to
reversal of this phenotype by suppressing ZEB1, ZEB2 and
snail2 expression. A recent report documents a tumor-
suppressive role of miR-205 in human prostate by counter-
acting epithelial-to-mesenchymal transition and reducing cell
migration/invasion (66). Significantly lower miR-205 expres-
sion levels were found in cancer than in normal prostate cell
lines as well as in tumor compared with matched normal
prostate tissues, with a particularly pronounced reduction in
carcinomas from patients with local-regionally disseminated
disease. Restoring the expression of miR-205 in prostate
cancer cells resulted in cell rearrangements consistent with a
mesenchymal-to-epithelial transition, such as upregulation of
E-cadherin and reduction of cell motility and invasion, and
in the downregulation of several oncogenes known to be
involved in disease progression (i.e., interleukin 6, caveolin-1,
EZH2). These events are presumably driven by the
concurrent repression of specific predicted miR-205 targets,
namely N-chimaerin, ERBB3, E2F1, E2F5, ZEB2, and
protein kinase Cε. Strikingly, protein kinase Cε seemed to
play a direct role in regulating epithelial-to-mesenchymal
transition (66).
Downregulation of miR-146a has also been reported in
prostate cancer (67). Transfection of miR-146a in PC-3
prostate cancer cells suppressed the Rho-associated protein
kinase ROCK1 and markedly reduced cell proliferation,
invasion, and metastasis to human bone marrow endothelial
cell monolayers (67). Similarly, miR-373 and miR-520c are
downregulated in prostate cancer. These miRs target the
adhesion receptor CD44 and enhance invasion of prostate
cancer cells in vitro (68). Prostate cancer cells are deficient in
an intronic miRNA- miR-126* as the expression of its host
gene, EGF-like domain 7 (Egfl7), is attenuated in prostate
cancer (69). miR-126* causes translational repression of
prostein, a prostate-specific antigen that leads to reduced
migratory and invasive potential of LNCaP cells (69).
miR-330 is another tumor suppressive miR that has
been reported to be significantly under expressed in human
prostate cancer. miR-330 targets E2F1 and induces
apoptosis in prostate cancer cells through E2F1-mediated
suppression of Akt phosphorylation (70). Similarly, in vitro
and in vivo studies showed that miR-17-3p is a prostate
tumor suppressor (71). The expression of miR-17-3p is
decreased in high-grade prostate tumors analyzed by laser
capture microdissection-purified clinical human prostatec-
tomy specimens. Downregulated expression of miR-17-3p
correlates with increased vimentin expression and tumori-
genicity (71). miR-331-3p expression is also decreased in
prostate cancer tissue relative to normal adjacent prostate
tissue (72). Reintroduction of miR-331-3p reduced ERBB-2
tyrosine kinase receptor that is frequently overexpressed in
prostate cancer and is associated with disease progression
and poor survival. Also, miR-331-3p transfection blocked
the androgen receptor signaling pathway in prostate cancer
cells, reducing activity of an androgen-stimulated prostate-
specific antigen promoter and blocking prostate-specific
antigen expression (72). Ectopic expression of miR-331-3p
in prostate cancer cell lines LNCaP and VCaP induces
apoptosis and growth arrest concomitant with a repression
of Cell division cycle associated 2 (CDCA5) and Kinesin
family member 23 (KIF23) genes (51).
Oncogenic MicroRNA in Prostate Cancer
miR-21 was identified as an androgen receptor-regulated
miRNA whose levels are elevated in prostate cancer com-
pared with adjacent normal tissue (52). Inhibition of miR-21
diminished androgen-induced PCa cell proliferation,
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tumor growth and castration resistance in vivo (52). In a
separate study, miR-21 levels were reported to be elevated
in androgen-independent prostate cancer cell lines DU145
and PC-3 (73). Inactivation of miR-21 by antisense
oligonucleotides in these cell lines resulted in enhanced
sensitivity to apoptosis and inhibition of cell motility and
invasion. miR-21 targets Myristoylated alanine-rich protein
kinase c substrate (MARCKS), which plays key roles in cell
motility and cell adhesion, suggesting that miR-21 could
promote apoptosis resistance, motility, and invasion in
prostate cancer cells (73). Also, it has been reported that
miR-21 directly targets bone morphogenetic protein recep-
tor II (BMPRII), suggesting that miR-21 may have a
potential role in regulating the malignancy and metastatic
abilities of prostate cancer cells (74).
Shi et al. (2007) reported that miR-125b is an androgen-
regulated miR that is upregulated in androgen-independent
prostate cancer cells (75). Furthermore, transfection of
synthetic miR-125b in LNCaP cells stimulated androgen-
independent growth and downregulated the expression of
Bak1, a pro-apoptotic gene of the Bcl-2 family (75). Also,
miR-32 is upregulated in prostate cancer and regulates the
expression of Bim, a pro-apoptotic member of the Bcl-2
family. Downregulation of Bim can contribute to the
resistance of tumor cells to death stimuli (48).
miR-221 and miR-222 are two highly homologous
microRNAs whose upregulation has been recently described
in various cancers, including prostate cancer (50,76–79).
Galardi et al. (2007) reported that miR-221 and miR-222,
encoded in tandem on chromosome X, are over-expressed
in the PC3 cellular model of aggressive prostate carcinoma,
as compared with LNCaP and 22Rv1 cell line models of
slowly growing carcinomas (76). Over-expression of miR-
221/222 in LNCaP cells enhanced the clonogenicity and
growth potential in vitro and in vivo by inducing a G1 to S-
phase shift in the cell cycle. Inhibition of miR-221 and miR-
222 expression by antisense LNA oligonucleotides or
antagomir treatment strongly reduced the clonogenicity
and tumorigenicity of PC3 cells (76,77). miR-221 and
miR-222 directly targets the cyclin-dependent kinase
(CDK) inhibitor p27(Kip1) contributing to the oncogenesis
and progression of prostate carcinoma through p27(Kip1)
downregulation (76,77). Another study suggests the involve-
ment of miR-221 and miR-222 in the development or
maintenance of the castration-resistant prostate cancer
phenotype (78). miR-221 and miR-222 expression levels
were reported to be significantly increased in an androgen-
independent cell-line LNCaP-Abl as compared with the
androgen-dependent prostate cancer cell line LNCaP.
Overexpression of miR-221 or miR-222 in androgen-
dependent cell lines significantly reduced the level of the
dihydrotestosterone (DHT), induced upregulation of
prostate-specific antigen (PSA) expression and increased
androgen-independent growth. Antagonism of miR-221 and
miR-222 in the LNCaP-Abl cell line restored the response
to the DHT induction of PSA transcription and also
increased the growth response of the LNCaP-Abl cells to
the androgen treatment (76,77). Contrary to these studies, a
recent report suggests that expression of microRNA-221 is
progressively reduced in aggressive prostate cancer and
metastasis (80).
miR 17-92 cluster have been ascribed oncogenic roles in
prostate cancer. Overexpression of a member of the mir-17-
92 cluster, miR-20a, decreased apoptosis in a prostate cancer
cell line, while inhibition of miR-20a by an antisense oligo-
nucleotide resulted in increased cell death after doxorubicin
treatment (81). miR-20a directly represses E2F1, E2F2 and
E2F3 (45,81). E2F1 along with p21/WAF1 is also a target
for miR-106b cluster that plays anti-apoptotic and growth-
inhibitory roles in prostate cancer (48).
In summary, these studies suggest that miRNAs act as
tumor suppressors as well as oncogenes and are involved in
the etiology of prostate cancer.
DIET AND MICRORNA
The molecular pathology of prostate cancer is complex; not
only are multiple genetic and epigenetic events involved in
its pathogenesis, but additional environmental factors such
as dietary components are also involved (2,39). Although
epidemiologically CaP can be divided into hereditary and
sporadic forms, most PCa seem to be sporadic with <10%
inherited (2). Dietary factors are believed to contribute to
differences in cancer incidence among populations with
different dietary habits and life-styles. In the United States,
the incidence of prostate cancer is highest in African-
Americans, followed by Caucasians, Hispanics, Asian/
Pacific Islanders, and American Indians (39). Dietary
factors may influence the risk of prostate cancer, and some
factors may possess chemopreventive and therapeutic
potential in prostate cancer. Experimental evidence sug-
gests that dietary factors play a crucial role in prostate
carcinogenesis by affecting fundamental cellular processes
involved in carcinogenesis, including apoptosis, cell-cycle
control, angiogenesis, inflammation, and DNA repair (2).
Since miRNAs influence these biological processes as well,
it is not surprising that there is an interplay between dietary
factors and microRNAs that ultimately affects the process
of malignant transformation. A few reports discussed below
suggest that dietary modulation of miRNA expression may
contribute to the cancer-protective effects of dietary
components. However, this area is still emerging and needs
further investigations. To our knowledge, there are no
reports on diet and miRNA in prostate cancer. Below we
1020 Saini, Majid and Dahiyagive a brief account of the reports in other cancers that gives
a flavor of the miRNA-diet connection that advocates
investigation in this direction in PCa.
Genistein
Epidemiological data suggest that the rates of clinically
significant prostate cancer are 15-fold higher in men from
the United States than in men from Asian countries (82),
attributable to the fact that Asian diet comprises a
significant portion of soybean-enriched foods. Genistein,
an isoflavone isolated from soybean, has been found to be a
potent antitumor agent. However, the precise mechanism
by which genistein suppresses tumorigenesis remain unclear.
Our group has been exploring the chemopreventive effects
of genistein in prostate cancer and other malignancies.
Several studies suggest that the inhibition of human cancer
cell growth by genistein is mediated via the modulation of
genes that are related to the control of cell cycle, apoptosis,
angiogenesis, invasion, and metastasis (83,84). Genistein
induces the p21WAF1/CIP, p16INK4a and other tumor
suppressorgenesinprostatecancercellsbyepigeneticmecha-
nisms involving active chromatin modifications (85–88). It
has been shown that genistein inhibits the activation of
NF-kappaB and Akt signaling pathways, both of which
are known to maintain a homeostatic balance between cell
survival and apoptosis. Moreover, genistein antagonizes
estrogen- and androgen-mediated signaling pathways,
possesses antioxidant properties, and is a potent inhibitor
of angiogenesis and metastasis. Due to its pleiotropic anti-
cancer activities, genistein is a promising agent for prostate
cancer chemoprevention (83,84).
Sun et al. (2009) explored the possible activity of
genistein to inhibit human uveal melanoma cell growth
and investigated the effect of genistein on microRNA-27a
(miR-27a) and its cognate targets (89). The results suggested
that genistein significantly inhibits uveal melanoma cell
growth in a time- and dose-related manner in vitro and in
vivo. Functional assays revealed that the levels of miR-27a
and its target gene zinc finger and BTB domain containing
10 (ZBTB10) were significantly different based on the dose
of genistein, suggesting a correlation between antitumor
activity of genistein and miR-27a-mediated regulatory
mechanism (89). Another study reports the modulation of
miR-16 effects by genistein in a malignant B-1 cell line
derived from a murine chronic lymphocytic leukemia (CLL)
model (90). Alterations in the human 13q14 genomic region
containing mir-15a and mir-16-1 are present in most
human chronic lymphocytic leukemia (CLL) leading to a
decrease in mature miR-16 and miR-15a levels. Augmen-
tation of miR-16 leads to an accumulation of cells in the G1
phase of the cell cycle and increased apoptosis. Combining
miR-16 with genistein resulted in a significant synergistic
induction of apoptosis, suggesting that genistein can poten-
tially modulate the biological effects of microRNAs (90).
Curcumin
Curcumin (diferuloylmethane), a naturally occurring flava-
noid and proapoptotic compound derived from the
rhizome of Curcuma longa, has been shown to have anti-
cancer effect in various cancers, including prostate (91–98).
In vitro and in vivo preclinical studies have shown that
curcumin has antioxidant, anti-inflammatory, antiprolifer-
ative, and proapoptotic activities. Curcumin putatively
downregulates the expression of gene products such as
nuclear factor-κB, suppresses growth, induces apoptosis,
and modulates various signal transduction pathways and
the expression of many oncogenes (98,99). It has been
found that curcumin downregulates the transactivation and
expression of AR and AR-related molecules (AP-1 and NF-
κB) in prostate cancer cell lines (98).
A recent study shows that curcumin alters the miRNA
expression profiles in human pancreatic cancer cells
(100,101). The potential effects of curcumin (10 μmol/L)
on miRNA expression profiles were studied in a pancreatic
cancer cell line, BxPC3 which showed that 11 miRNAs
were significantly upregulated, whereas 18 were significant-
ly downregulated by curcumin compared with the control.
Among these altered miRNAs, miRNA-22 was up-
regulated, whereas miRNA-199a* was downregulated by
curcumin. miR-22 upregulation was accompanied by
repression of its target genes SP1 transcription factor
(SP1) and estrogen receptor 1 (ESR1), suggesting that
modulation of miRNA expression may be an important
mechanism underlying the biological effects of curcumin
(101). Another study shows upregulation of miR- 15a and
miR-16 expression in curcumin-treated MCF-7 breast
cancer cells. Both miR-15a and miR-16 could inhibit the
expression of Bcl-2, thereby inducing apoptosis in these
cancer cells (102).
Retinoic Acid
Several reports on another dietary component, retinoic
acid, suggest its ability to modulate miRNA expression as
detailed below.
Acute promyelocytic leukemia (APL) is caused by a novel
fusion protein (PML-RAR-α) resulting from the reciprocal
translocation between the retinoic acid receptor-α (RAR-α)
on chromosome 17 with the promyelocytic leukemia gene
(PML) on chromosome 15 (103). In the absence of an
adequate dose of retinoic acid (RA), this fusion protein
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pressor complex that binds to target promoters, resulting in
transcriptional repression of retinoic acid-responsive genes
These effects get reversed by pharmacological doses of
all-trans-retinoic acid (ATRA) (103). Recent studies sug-
gest that these effects are mediated through miRNAs as
summarized below.
Careccia et al. (2009) analysed the expression of 12
granulocytic differentiation signature miRNAs in a cohort
of APL patients successfully treated with ATRA and
chemotherapy and reported a downregulation of miR-
181b and upregulation of miR-15b, -16, -107, -223, -342
and let-7c (104). Further, it was found that PML/RARα
binds the regulatory sequences of the intragenic miR-342
and let-7c, and in response to ATRA, the PML/RARα is
released, leading to the transcriptional activation of these
microRNAs together with their host genes (104). Similarly,
Garzon et al. (2007) analysed microRNA gene expression
during retinoic acid-induced differentiation of human acute
promyelocytic leukemia and found that ATRA causes
upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3,
let-7c, let-7d, miR-223, miR-342 and miR-107, whereas
miR-181b was downregulated (105). To understand the
ATRA-mediated regulation of miRNAs, a search for
ATRA-modulated transcription factor binding sites in the
upstream genomic region of the let-7a-3/let-7b cluster
identified several putative nuclear factor-kappa B (NF-κB)
consensus elements. Functional assays could validate one
proximal NF-κB binding site as essential for the ATRA-
mediated transactivation of the let-7a-3/let-7b cluster. Also,
it was shown that the downregulation of RAS and Bcl2 after
ATRA treatment correlates with the activation of known
miRNA regulators of those proteins, let-7a and miR-15a/
miR-16-1, respectively (105). Another group identified miR-
342 as one of the microRNAs upregulated by ATRA during
APL differentiation, which is a direct transcriptional target
of the critical hematopoietic transcription factors PU.1 and
interferon regulatory factor (IRF)-1 and IRF-9 (106). IRF-1
maintains miR-342 at low levels, whereas the binding of
PU.1 and IRF-9 in the promoter region following retinoic
ATRA-mediated differentiation upregulates miR-342 ex-
pression. Enforced expression of miR-342 in APL cells
stimulated ATRA-induced differentiation (106).
miR-10a overexpression is a key mediator of metastatic
behavior in pancreatic cancer, which regulates metastasis
via suppression of HOX genes, HOXB1 and HOXB3. miR-
10a is a retinoic acid target, and retinoic acid receptor
antagonists effectively repress miR-10a expression and
completely block metastasis (107). miR-34a functions as a
potential tumor suppressor in neuroblastoma cells, and
retinoic acid-induced differentiation of the neuroblastoma
cell line led to increased miR-34a expression and decreased
expression of its target E2F3 (108).
miR-23 has a critical role in the RA-induced neuronal
differentiation of human embryonal carcinoma NT2 cells
(109). Retinoic acid downregulates several microRNAs
(i.e., miR-9/9*, miR-124a, and miR-125B) to induce
abnormal development of the spinal cord in a spina
bifida rat model (107).
Folate and Methyl Deficiency
It has been proposed that DNA methylation may mediate
some of the effects of environmental exposures and lifestyle
factors on disease risk, as methyl-deficient diets influences
global DNA methylation (110). A case-control study of
1,294 prostate cancer patients and 1,451 controls also
supports a favorable role of dietary folate on prostate
cancer risk (111).
Experimental rats fed a folate- methionine- and choline-
deficient diet develop hepatocellular carcinoma (HCC) at
54 weeks of age in the absence of carcinogen treatment
(112). miRNA expression analysis of livers from the animals
fed the folate-/methyl-deficient diet showed let-7a, miR-21,
miR-23, miR-130, miR-190, and miR-17-92 family of
genes were upregulated, whilst miR-122, an abundant
liver-specific miR, was downregulated in the tumors. The
decrease in hepatic miR-122 was a tumor-specific event
because it did not occur in rats switched to the folate- and
methyl-adequate diet after 36 weeks on the deficient diet,
which did not lead to hepatocarcinogenesis (112). In
another study, it was reported that HCC induced by
methyl deficiency was characterized by profound down-
regulation of tumor suppressor miR-34a, miR-16a, miR-
181a, and miR-127. This was accompanied by alterations
i np r o t e i nl e v e l so ft h eE 2 F 3a n dB C L 6 ,w h i c ha r e
confirmed targets for miR-34a and miR-127, respectively
(100,113). A recent study shows that feeding choline-
deficient and amino acid-defined diet to experimental mice
promotes hepatocarcinogenesis accompanied by altered
microRNA expression profiles that includes an up-
regulation of oncogenic miR-155, miR-221/222, and
miR-21 and downregulation of miR-122 at early stages of
hepatocarcinogenesis (114). Another study shows down-
regulation of the microRNAs involved in the regulation of
apoptosis, cell proliferation, cell-to-cell connection, and
epithelial-mesenchymal transition, including miR-34a, miR-
127, miR-16a and miR-200b, in rat liver during hepato-
carcinogenesis induced by a methyl-deficient diet (115).
Folate deficiency induced a pronounced global increase
in miRNA expression in human lymphoblastoid cells (116).
miR-222 was identified as significantly overexpressed under
folate-deficient conditions in vitro, and this finding was
confirmed in vivo in human peripheral blood from individuals
with low folate intake, suggesting that miRNA expression
1022 Saini, Majid and Dahiyamight be potential biomarkers of nutritional status in
humans (116).
Other Dietary Factors
Maternal high fat diet during pregnancy and lactation
induced coordinated and long-lasting changes in the
expression of insulin-like growth factor2 (Igf2) and several
key miRNAs in the offspring (117). Another study explored
the effect of n-3 polyunsaturated fatty acids on carcinogen-
directed non-coding microRNA signatures in rat colon
(118). Experimental rats were fed diets containing corn oil
or fish oil with pectin or cellulose and injected with a colon-
specific carcinogen, and effects on microRNA expression in
colonic mucosa were analysed. At an early stage of cancer
progression, five different miR (let-7d, miR-15b, miR-107,
miR-191 and miR-324-5p) were significantly affected by
diet-carcinogen interactions. Overall, fish-oil-fed animals
exhibited the smallest number of differentially expressed
microRNAs pointing to a novel role of fish oil in protecting
the colon from carcinogen-induced microRNA dysregula-
tion (118). Melkamu et al. (2009) studied the modulation of
miR expression by the chemopreventive agent indole-3-
carbinol in induced mouse lung tumors and found that the
levels of miR-21, mir-31, miR-130a, miR-146b, and miR-
377 were reduced in indole-3-carbinol-fed mice relative to
the level in mice treated with the carcinogen alone (119).
CONCLUSIONS
Experimental evidence suggests a role for miRNAs in the
etiology of prostate cancer. However, our current under-
standing in this area is still limited, and more focused
functional studies are required to decipher the precise
miRNA signatures for prostate cancer. Overall, a better
understanding of miRNA-regulated pathways in prostate
cancer will improve our knowledge of the pathogenesis of
the disease and can potentially aid in developing miRNA-
based diagnostic and therapeutic strategies for the manage-
ment of prostate cancer. The potential application of
miRNAs in prostate cancer is elegantly demonstrated in a
study by Mitchell et al. (2008), where serum levels of miR-
141 (a miRNA expressed in prostate cancer) can distinguish
patients with prostate cancer from healthy controls (120).
Also, it is being recognized that dietary components such as
genistein, curcumin, folate and retinoids can affect carcino-
genesis through modulation of miRNA expression patterns.
Such studies are urgently needed in regards to prostate
cancer given the fact that dietary components have been
shown to play a crucial chemopreventive role in prostate
cancer progression and metastasis.
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